Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $54.20 Consensus Price Target from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received a consensus recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $54.20.

Several research analysts have commented on the stock. William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. The Goldman Sachs Group increased their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a report on Friday, November 15th. Finally, Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th.

Tarsus Pharmaceuticals Trading Up 0.6 %

Shares of TARS opened at $54.35 on Tuesday. Tarsus Pharmaceuticals has a 1-year low of $18.99 and a 1-year high of $56.77. The company has a market capitalization of $2.08 billion, a P/E ratio of -14.27 and a beta of 1.04. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The firm’s 50 day simple moving average is $47.88 and its 200 day simple moving average is $35.62.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TARS. Allspring Global Investments Holdings LLC raised its position in shares of Tarsus Pharmaceuticals by 16.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock worth $6,924,000 after acquiring an additional 29,465 shares in the last quarter. Creative Planning bought a new position in Tarsus Pharmaceuticals in the third quarter worth $362,000. Vestal Point Capital LP purchased a new position in Tarsus Pharmaceuticals during the third quarter valued at $7,565,000. Essex Investment Management Co. LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at $3,590,000. Finally, Verition Fund Management LLC bought a new stake in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at $763,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.